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Abstract
Introduction: Esophageal cancer is an increasingly common type of neoplasm with a very poor prognosis. This
prognosis could improve with more early tumor detection. We have previously shown that we can use an optical
spectroscopy to detect ﬁeld cancerization in the buccal mucosa of patients with laryngeal cancer. The aim of this
prospective study was to investigate whether we could detect ﬁeld cancerization of buccal mucosa of patients with
esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC).
Methods: Optical measurements were performed in vivo using a novel optical technique: multidiameter single-ﬁber
reﬂectance (MDSFR) spectroscopy. MDSFR spectra were acquired by a handheld probe incorporating three ﬁber
diameters. Multiple absorption and scattering parameters that are related to the physiological and ultrastructural
properties of the buccal mucosa were derived from these spectra. A linear discriminant analysis of the parameters was
performed to create a combined biomarker σ to discriminate oncologic from non-oncologic patients.
Results: Twelve ESCC, 12 EAC, and 24 control patients were included in the study. The median value of our biomarker
σ was signiﬁcantly higher in patients with ESCC (2.07 [1.93–2.10]) than control patients (1.86 [1.73–1.95], p= 0.022).
After cross-validation σ was able to identify ESCC patients with a sensitivity of 66.7% and a speciﬁcity of 70.8%. There
were no signiﬁcant differences between the EAC group and the control group.
Conclusion: Field cancerization in the buccal mucosa can be detected using optical spectroscopy in ESCC patients.
This may be the ﬁrst step towards non-invasive ESCC cancer screening.
Introduction
Esophageal cancer (EC) is an increasingly common type
of neoplasm with a very poor prognosis. Worldwide, an
estimated 450,000 new EC cases and 400,000 deaths
occurred in 2012, making it the 8th most common type of
cancer1. The vast majority of EC are squamous cell
carcinoma (ESCC) or adenocarcinoma (EAC). Early
diagnosis and treatment of (pre)cancerous lesions could
greatly improve the overall patient outcome2. Unfortu-
nately, about 60% of patients are diagnosed with an
incurable locally advanced or metastatic EC3.
A promising new approach for cancer detection is
focused on ﬁeld cancerization (FC). FC is the notion that
the initial tissue changes that lead to a neoplasm, do not
only occur in the tumor site itself, but instead affect an
entire organ or tract4. These tissue changes include
alterations in the microvasculature and the tissue nanos-
cale architecture, such as the organization of the
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cytoskeleton and the size and structure of cell nuclei and
organelles5,6. In the case of EC, it is presumed that FC
encompasses the entire upper aerodigestive tract. This is
supported by the high incidence of second primary
tumors in patients with esophageal, but also head and
neck and lung, carcinoma7. Optical techniques, such as
reﬂectance spectroscopy, have the potential to detect
tissue changes caused by FC. Accurate optical detection of
FC in an easily accessible, non-invasive anatomic location,
such as the buccal mucosa, could potentially be used to
detect distant EC4,8,9.
A number of studies investigated similar approaches for
early tumor detection. The ﬁrst study analysed cells of the
cytologically normal proximal esophagus of patients with
distal EAC ex vivo with partial wave spectroscopy10. Eso-
phageal adenocarcinoma (EAC) patients were shown to
have a 1.8-times higher (p= 0.01) disorder strength, a
parameter that is closely related to FC, than non-oncologic
controls. A different ex vivo optical technique was used to
detect FC in rectal mucosa biopsies to diagnose colorectal
neoplasia11. This could predict the presence of an advanced
adenoma with a promising sensitivity of 100% and a spe-
ciﬁcity of 80%. An ﬁnal interesting study used a new in vivo
optical technique to detect FC in the buccal mucosa of lung
cancer patients12. Their optical biomarker was able to
predict the presence of lung cancer with a sensitivity of 79%
and a speciﬁcity of 83%. These studies illustrate the promise
of optical detection of FC at a distant anatomic site than the
actual malignancy.
Our group has recently developed a novel optical tech-
nique, multidiameter single-ﬁber reﬂectance (MDSFR)
spectroscopy, which enables non-invasive quantiﬁcation of
the optical properties of tissue using a simple ﬁber-optic
probe. MDSFR spectroscopy combines data from multiple
single ﬁber reﬂectance (SFR) spectra. One SFR spectrum
contains the combined information on how much light has
been absorbed and scattered in tissue. From such a reﬂec-
tance spectrum, the tissue absorption coefﬁcient (μa) can be
quantiﬁed. Spectral deconvolution of μa yields measure-
ments of several physiological parameters. Successive SFR
measurements with two or more ﬁber diameters enables the
quantiﬁcation of two scattering parameters, γ and μs’, that
are inﬂuenced by the angular scattering probability (phase
function)13–15. γ and μs’ are closely related to the nanoscale
architecture of tissue16. In a previous study, we used
MDSFR spectroscopy to detect FC in the buccal mucosa of
patients with laryngeal cancer17. The blood oxygen satura-
tion and BVF were lower in the buccal mucosa of patients
with cancer than the control group. The combined para-
meter α was able to predict the presence of a tumor with a
sensitivity of 78% and a speciﬁcity of 74%.
This study describes the ﬁrst attempt to use reﬂectance
spectroscopy of the buccal mucosa to assess if FC is
present in EC. Again, we do this by measuring the optical
properties of the buccal mucosa of patients with and
without cancer. Differences in the values of our absorp-
tion and scattering parameters could indicate the pre-
sence of FC. The presence of FC may then be used to
identify patients with EC. If proven feasible, this study
would be the ﬁrst step toward implementing this method
as a detection tool for EC.
Methods
Subjects and examination procedure
This prospective study was approved by the Medical
Ethics Committee of the Erasmus MC Cancer Institute.
Patients were recruited from the outpatient clinic of the
Gastroenterology and Hepatology department between
December 2015 and January 2017. Clinical parameters
such as: gender, age, medical history, smoking (pack-
years), and TNM-stage of tumor were collected using the
electronic medical record (CSC-iSOFT, Virginia, USA).
The oncologic group of patients consisted of patients with
primary and untreated esophageal squamous cell carci-
noma (ESCC) and EAC. Tumors of all TNM-stages were
included. The ESCC and EAC were conﬁrmed by an
endoscopic examination and histopathology. The non-
oncologic control group consisted of patients that
underwent endoscopic examination for a variety of
complaints, e.g., gastro-esophageal reﬂux, dysphagia, and
abdominal pain. The absence of an occult, unexpected
malignancy or Barrett’s esophagus was conﬁrmed during
Fig. 1 Application of the multidiameter single-ﬁber reﬂectance spectroscopy probe on the buccal mucosa. a Overview picture with in the
background spectra on laptop. b Detail of probe contact with buccal mucosa. c Detail of probe tip angled at 15 degrees. 180 × 46mm (300 × 300 DPI)
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the endoscopic examination. Patients with a medical
history of head and neck or lung cancer were excluded
from all study groups. Informed consent forms were
signed before inclusion in this study by all patients.
The multidiameter SFR measurements of the buccal
mucosa were performed before the endoscopic examina-
tion (Fig. 1). All measurements were done by a single
investigator (OB). The probe tip was gently placed in
contact with the buccal mucosa, after disinfecting the
ﬁber bundle with Tristel Trio (Tristel Solutions Ltd,
Snailwell, UK). Five consecutive MDSFR measurements
were performed without moving the probe tip. The total
duration of these measurements was approximately forty
seconds.
MDSFR device
The absorption and scattering properties of the buccal
mucosa were quantiﬁed with a custom made MDSFR
spectroscopy device. In a previous paper, we have
described it in detail18. In summary, MDSFR spectroscopy
uses one ﬁber bundle for both light delivery and collec-
tion. The ﬁber has 19 cores of 200 μm ﬁbers. Each ﬁber in
the ﬁber bundle is trifurcated at the proximal end into a
ﬁber delivering light from a halogen lamp, a ﬁber deli-
vering light from a 365 nm and 405 nm LED, and a ﬁber
collecting light to the spectrometer. At the ﬁber tip, the
ﬁbers are bundled into three concentric groups compro-
mising one, six, and twelve ﬁbers. To avoid collection of
specular reﬂection, they are polished at an angle of 15
degrees. The last 10 cm of the ﬁber bundle is at the distal
end encased in a 12mm diameter curved metal housing.
This metal housing ensures optimal application on buccal
mucosa (Fig. 1). A series of ﬁber optic interconnects and
three computer-controlled shutters enable illumination
and spectroscopic detection of independent ﬁber groups.
This allows sequential SFR measurement of 200, 600, and
1000 μm to be made without moving the probe. Addi-
tional ﬂuorescence measurements are made by illumi-
nating all ﬁbers in the bundle by the 365 nm LED and
consecutively the 405 nm LED. The entire device is por-
table and approved for use in the outpatients clinic. A
detailed description of the calibration procedure has been
described previously18.
The nature of FC requires that the tissue optical prop-
erties are measured superﬁcially. The maximal sampling
depth of MDSFR spectroscopy (500 μm) is well matched
with the thickness of the epithelial layer of the buccal
mucosa (250–350 μm) and the underlying vascularized
layer of the lamina propria (300–350 μm)19,20.
Spectral analysis
A previous paper by our group describes the complete
analysis of spectra in detail21. First, the individual SFR
spectra of the 200, 600, and 1000 μm ﬁbers are used to
calculate the tissue absorption properties. The
absorption-corrected spectra of multiple ﬁber diameters
were then combined to determine the tissue scattering
properties: μs’ (mm
−1), and γ (−). Next, we can extract
four physiological parameters from the 1000 μm SFR ﬁt:
microvascular blood oxygen saturation (StO2 (%)), blood
volume fraction (BVF (%)), mean vessel diameter (VD
(mm)) and tissue bilirubin concentration ([BIL]tis (μmol/
L). Finally, the intrinsic ﬂuorescence is calculated from
the raw ﬂuorescence spectrum using the optical proper-
ties that are previously measured with MDSFR spectro-
scopy. This quantity is given by the product of the
absorption coefﬁcient of the tissue ﬂuorophores at the
excitation wavelength μfa,x and their quantum efﬁciency
across the emission spectrum Q (−).
Statistical analysis
The optical parameters were calculated by averaging the
ﬁve buccal mucosa measurements taken per patient
weighted by the individual conﬁdence intervals of the
ﬁtted parameters. Twelve parameters were analysed: StO2,
BVF, VD, [BIL]tis, μs’ at 450 and 800 nm, μs’ power law
scattering parameter, γ at 450 and 800 nm, average γ and
intrinsic ﬂuorescence under 365 and 405 nm excitation.
Our quantitative variables were not normally distributed.
We thus report our results as median value and inter-
quartile range (IQR). Differences between two groups
were analysed using the t-test (normally distributed data)
or the Mann-Whitney U test (non-normally distributed
data). Qualitative data was reported as counts and per-
centages, and differences between groups were analysed
using the chi-squared test or the Fisher’s exact test. Binary
logistic regression was used to investigate if the outcome
parameters could predict the presence of a malignancy.
The age at measurement was included in the analysis as a
covariate. We standardized our data to a standard normal
distribution (xnew= (x – μ)/sd, where μ is the mean and sd
is the standard deviation of parameter x) to compute a
biomarker to identify EC patients. A linear discriminant
analysis of the parameters was performed to create a
combined biomarker σ A ROC-curve of σ was created to
perform a sensitivity and speciﬁcity analysis. A leave-one-
out cross-validation was performed to test the robustness
of σ. There was no missing data. Statistical analysis was
performed using SPSS version 21 (IBM Co., Armonk, NY,
USA) and the cut off point for signiﬁcance was p < 0.05.
Results
Forty-eight patients were included in this study: 12
patients with ESCC, 12 patients with EAC and 24 control
patients (Table 1). The percentage of males was higher in
both the ESCC 7/12 (58.3%) and EAC group 11/12
(91.7%), than in the controls 10/24 (41.7%), p= 0.004. The
median age of the patients was 69.9 (64.1–74.8) years in
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the ESCC group and 68.3 (64.8–71.8) years in the EAC
group. This was higher than the 61.2 (54.9–69.0) years in
the control group. The median amount of pack-years was
27.5 (6.3–30.0), 16.5 (6.3–33.8), and 4.0 (0.0–30.0) in the
ESCC, EAC and control group respectively.
Table 2 shows the TNM-classiﬁcation and location of
the ESCC and EAC. T-stage was equally divided over the
two types of EC. ESCC were staged as T1 in two (16.7%),
T3 in nine (75.0%), and T4 in one (8.0%) cases and EAC
were staged as T1 in two (16.7%), T2 in one (8.3%), and
T3 in nine (75.0%) cases. Most tumors were not metas-
tasized to regional lymph nodes, N0 in eight (66.6%)
patients in ESCC group and four (33.3%) patients in EAC
group. Tumors were staged N1 and N2 in two (16.7%)
cases in the ESCC group and in four (33.3%) cases in the
EAC group. Distant metastasis (M1) was found in one
ESCC and one EAC patient. ESCC was located in the
upper, middle, and lower esophagus in two (16.7%) six
(50.0%) and four (33.3%) cases. All EAC tumors were
located in the lower esophagus.
The intra-patient variation of the ﬁve consecutive
measurements varied between 3.7 and 24.8% deviation
from the mean for the twelve MDSFR parameters. This
variation was similar to measurements in two previous
studies17,22. μs’ at 450 nm varied 9.6%, at 800 nm 8.6%, and
the average μs’ parameter varied 17.9%. The values of the
three γ-parameters varies from 3.7 to 5.2%. The absorp-
tion parameters StO2, BVF, VD, and [BIL]tis varied slightly
more with intra-patient variations 8.0, 22.5, 18.2 and
24.8% respectively.
Based on a linear discriminant analysis of all the
MDSFR parameters, μs’ at 450 nm and μs’ at 800 nm were
combined into biomarker σ. μs’ at 450 nm and μs’ at 800
nm were the only two paramaters that were signiﬁcantly
different between the ESCC group and the controls. All
other parameters showed no signiﬁcant difference
between these two groups. Sigma had a 4% bigger area
under the curve than μs’ at 450 nm alone. It also sig-
niﬁcantly increased the sensitivity/speciﬁcity ratio.
Figure 2 shows that biomarker σ was signiﬁcantly
higher in patients with ESCC than non-oncologic con-
trols: 2.07 (1.93–2.10) vs. 1.86 (1.73–1.95), p= 0.022.
Logically, individual values of μs’ at 450 nm (p= 0.033)
and 800 nm (p= 0.029) were also higher in the ESCC
group than the control group (Fig. 2). Figure 3 shows a
ROC-curve of σ for the ESCC group with an area under
the curve of 75.7% (95% CI: 57.4–94.0). Biomarker σ was
able to differentiate patients with ESCC from controls
with a sensitivity of 66.7% and a speciﬁcity of 83.3%. A
leave-one-out cross-validation was performed to test the
robustness of sigma to predict patients with ESCC. This
slightly decreased the diagnostic performance to a sen-
sitivity of 66.7% and a speciﬁcity of 70.8%. Interestingly,
there was no correlation between smoking (packyears)
and biomarker sigma (r2== 0.0275 and standard error
of estimate= 0.1826).
There were no signiﬁcant differences in all paramaters
between the EAC group and the control group.






Male gender n (%) 10 (42) 7 (59) 11 (92)a
Age median (IQR) 61 (55–69) 70 (64–74)b 68 (65–72)b
Smoking PY median
(IQR)
4 (0–30) 28 (6–30)c 16 (6–34)
Smoking status n (%)
Never 11 (46) 2 (17)b 3 (25)
Past 9 (38) 6 (50) 7 (58)
Current 4 (17) 4 (33) 2 (17)
ESCC esophageal squamous cell carcinoma, EAC esophageal adenocarcinoma,
IQR inter quartile range, PY pack-year
ap-value < 0.05 compared to controls
bp-value < 0.1 compared to controls
cp-value is NOT signiﬁcantly different (p= 0.182). p-values calculated with χ2 test
(gender and smoking status) and Mann-Whitney U test (age and smoking PY)
Table 2 TNM-classiﬁcation and location of ESCC and EAC
tumors
ESCC (n (%)) EAC (n (%))
T-stage
I 2 (17) 2 (17)
II – 1 (8)
III 9 (75) 9 (75)
IV 1 (8) –
N-stage
0 8 (67) 4 (33)
I 2 (17) 4 (33)
II 2 (17) 4 (33)
III – –
M-stage
0 11 (92) 11 (92)
1 1 (8) 1 (8)
Location
Upper 2 (17) –
Middle 6 (50) –
Lower 4 (33) 12 (100)
ESCC esophageal squamous cell carcinoma (n= 12), EAC esophageal adeno-
carcinoma (n= 12), – 0 cases
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Discussion
This study demonstrates that FC is present in the buccal
mucosa of patients with ESCC and that it can be detected
using optical spectroscopy. Multiple absorption and
scattering parameters were measured with MDSFR spec-
troscopy. We found that our biomarker σ which is a
combination of μs’ at 450 and 800 nm, was signiﬁcantly
higher in patients with ESCC than in non-oncologic
controls. Sigma was able to identify patients with ESCC
with a sensitivity of 67% and a speciﬁcity of 70.8%.
Unfortunately, σ could not distinguish patients with EAC
from controls.
Our main result showed the ﬁrst proof that the buccal
mucosa of patients with ESCC is altered. The increase of
scattering parameter μs’ indicates that alterations in the
nano-architecture of the buccal mucosa have occurred.
Studies have shown that an increase in scattering events
correlates with increase of the local density of macro-
molecules and changes in their organisation23. These
alterations are key elements of FC24. Our ﬁndings conﬁrm
the results of a similar study that used in vivo low-
coherence enhanced backscattering spectroscopy of the
buccal mucosa to identify patients with lung cancer12.
Their results also suggest that it is possible to detect
nano-architectural changes in the buccal mucosa in
patients with a tumor of the upper aerodigestive tract.
Their biomarker was able to identify patients with lung
cancer with a promising sensitivity of 79% and a speciﬁ-
city of 83% in their testing set. In a recent study, utilizing
MDSFR in patients with head and neck squamous cell
carcinoma cancer, we found that the physiological para-
meters (blood oxygen saturation and BVF) were altered
instead of scattering parameters such as μs’17. It is not yet
fully understood how this can be explained, since lar-
yngeal and EC patients share the same risk factors. It
might be that the FC has a different signature for different
types of malignancies. However, this hypothesis has to be
tested.
The results of the present study are promising with
regard to the use of MDSFR spectroscopy as an innovative
tool for early cancer detection. We chose a threshold that
resulted in a higher speciﬁcity than sensitivity. This will
result in a lower number of false positives and thus a
lower number of falsely diagnosed patients. On the other
hand, this will result in a relative high number of false
negatives, which means that the test will miss some
patients with malignancies25. A cost-effectiveness analysis
will have to be performed in a later stage to decide the
appropriate threshold and applicability of σ for detecting
ESCC.
Our approach, using MDSFR spectroscopy of the buccal
mucosa to identify patients with EC was more effective for
ESCC than EAC. This difference is expected because FC
in tissue partly develops due to exposure to carcinogens.
The carcinogens of ESCC and EAC differ. As such, the
main risk factors for ESCC are smoking and alcohol use,
while the main risk factor for EAC is gastric reﬂux. This
Fig. 2 Values of μs’ at 450 nm and 800 nm and biomarker σ
(combination of μs’ at 450 nm and 800 nm). Circles, triangles, and
squares represent means and error bars represent standard deviation.
ESCC esophageal squamous cell carcinoma, EAC esophageal
adenocarcinoma. *p= 0.030, †p= 0.045 and ‡p= 0.012. p-values were
calculated with a binary logistic regression with ‘age’ as a covariate. 87 ×
97mm (300 × 300 DPI)
Fig. 3 ROC curve of biomarker σ (composed of μs’ at 450 and 800
nm). AUC area under the curve. 87 × 86mm (300 × 300 DPI)
Bugter et al. Clinical and Translational Gastroenterology  (2018) 9:152 Page 5 of 7
Ofﬁcial journal of the American College of Gastroenterology
also explains why all EAC were located in the lower
esophagus, whereas most ESCC were located in the upper
and middle esophagus (Table 2). However, evidence for
FC of EAC was recently shown in a study in which
cytologically normal proximal esophageal squamous cells
were obtained by brushings during endoscopy. The dis-
order strength of these samples was signiﬁcantly higher in
patients with distal EAC (p < 0.01) and patients with distal
Barrett’s esophagus (p < 0.01) than healthy controls. This
indicates that proximal squamous cells might undergo
changes that are caused by distal EAC or Barrett’s eso-
phagus10. An important issue to address while discussing
an EC detection tool is that although ESCC is the pre-
dominant histological type of EC worldwide, this is not
the case in many developed countries. In developed
countries the incidence of EAC has been exceeding that of
SCC for some time with percentages reported of up to
80%. This highlights the need for a screening method for
EAC in the ‘western world’. Unfortunately MDSFR buccal
mucosa spectroscopy did not show to be effective for EAC
based on our results. It might however show value in high
ESCC incidence regions in Asia2.
In the present study we did not fully investigate the
effect of smoking. Smoking is known to cause mucosal
changes, some of which can lead to FC9. The exact rela-
tionship between smoking induced mucosal changes and
FC is unknown, e.g., patient A with 20 PY could have
extensive FC while patient B with the same amount of PY
has normal mucosa. This is underlined by the fact that the
lifetime risk of smokers to develop for instance lung
cancer is only 10%26. Ideally, in the present study, the
amount of pack years and distribution of current-smo-
kers, past-smokers, and non-smokers should have been
matched between the EC group and the controls.
Although these differences in our study were not sig-
niﬁcantly different, they were not matched. This could
have positively inﬂuenced our discriminative power to
identify ESCC patients (Fig. 3). Also due to the small
number of patients per group we were not able to take the
amount of pack years into our multivariate analysis of σ.
However we were able to do this in a previous study in
which we tested the discriminative power of α to identify
laryngeal cancer patients17. In that study smoking pack
years did inﬂuence the results, but not to a signiﬁcant
degree. Therefore, we believe that optical detection of FC
still shows promise for detecting ESCC patients.
There are a number of other potential limitations that
should be considered. One is the relatively small number
of patients per group, which might have had an inﬂuence
in multiple ways: (a) it prevents us from making deﬁnitive
statements about the discriminative power of the optical
detection of FC, (b) it could lead to an underestimation of
the signiﬁcance of differences between groups (p-value),
(c) we were not able to test the discriminative power of σ
on an independent training-set, and (d) we were only able
to correct our statistical analysis for one covariate: age.
However, age was also the only borderline signiﬁcantly
different baseline patient characteristic. Another possible
limitation is that the investigator who performed the
measurements (OB) was not blind to the oncologic status
of the patients. A ﬁnal point of attention is the fact that
the majority of patients in this cohort had advanced
tumors (T3). For a screening tool that ultimately has an
effect on patient survival the test performance char-
acteristics should be tested and found adequate in patients
with early EC, preferably T1 or T2. Survival in these
patients is signiﬁcantly better.
In conclusion, we have demonstrated that the reduced
scattering coefﬁcient, μs’, is increased in the buccal
mucosa of patients with ESCC. This increase could be
used to discriminate between patients with and without
ESCC based on an optical measurement of the buccal
mucosa. To our knowledge, this is the ﬁrst proof of the
concept that it is possible to detect ESCC by detecting FC
in the buccal mucosa. A larger study is now needed before
deﬁnitive conclusions on the potential role of MDSFR
spectroscopy detecting for ESCCC can be drawn.
Study Highlights
1. WHAT IS CURRENT KNOWLEDGE
● And increase in early tumor diagnosis will improve
esophageal cancer survival.
● Field cancerization detection could be used to
identify patients with unknown tumors.
2. WHAT IS NEW HERE
● Patients with esophageal squamous cell carcinoma
have ﬁeld cancerization in their buccal mucosa.
● This can be detected with detected in vivo with
reﬂectance spectroscopy.
● Reﬂectance spectroscopy may be uses as a non-
invasive esophageal cancer screening method.
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